North American AIDS Cohorts on Collaboration and Design (NAACCORD)

(no more than 30 lines) The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) has represented Region 1 of the leDEA initiative since 2006. The >20 single and multi-site clinical and classical epidemiologic HIV cohorts of the NA-ACCORD encompass most HIV cohorts within the United States (US). Over 100 sites contribute data collected from over 190,000 people with HIV (PWH). We have established a strong collaborative infrastructure that capitalizes on the talents and expertise of a multi-disciplinary group of investigators that span clinical research, epidemiology, data science and biostatistics. We have been highly productive in addressing our previous Aims and key questions in contemporary care and public health relevant to adult PWH. Our strengths are especially relevant to the goal of addressing the HIV epidemic in the US, uniquely providing the broad geographic and demographic scope, established scientific platform, large sample size, extensive longitudinal follow-up of >1.3 million person-years, and depth of clinical data to inform the goal to end the HIV epidemic with rich data on those who will continue to survive with HIV for decades after transmission is halted. Within this context, we present three broadly-defined aims for the next funding cycle: Aim 1: Characterize the longitudinal course of HIV treatment, progression and outcome, which will increase the number and heterogeneity of those in HIV care as HIV treatment and the long-term challenges of living with HIV continue to evolve. Aim 2: To assess and characterize the clinical course of HIV infection, with a focus on major chronic diseases and co-infections, multimorbidity and life expectancy. Aim 3: To expand and extend our state-of-the art epidemiologic, biostatistical, and data science methodologic approaches. The NA-ACCORD is a world-class collaboration of established HIV cohorts well-positioned to: a) provide in- depth understanding of the longitudinal course of HIV; b) understand differences in HIV treatment, outcomes and prognostic factors that will inform future research and HIV care; c) collaborate with the other IeDEA regions; and d) contribute to the continued development of methodology for large-scale longitudinal collaborative study designs.